Risks of the consumption of beverages containing quinine

Psychological Reports

Volumn 93, Issue 3 II, 2003, Pages 1022-1024

  Brašić, James Robert ^a,b,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; QUININE;

ACUTE KIDNEY FAILURE; ARTICLE; BEVERAGE; CHEMICALLY INDUCED DISORDER; DRINKING; HUMAN; LIVER FAILURE; MUSCLE SPASM; RISK FACTOR; THROMBOCYTOPENIA;

ANALGESICS, NON-NARCOTIC; BEVERAGES; DRINKING; HUMANS; KIDNEY FAILURE, ACUTE; LIVER FAILURE, ACUTE; QUININE; RISK FACTORS; SPASM; THROMBOCYTOPENIA;

EID: 1442303706     PISSN: 00332941     EISSN: 1558691X     Source Type: Journal    
DOI: 10.2466/pr0.2003.93.3f.1022     Document Type: Article

References (15)

1. BRAŠIĆ, J. R. (1999) Should people with nocturnal leg cramps drink tonic water and bitter lemon? Psychological Reports, 84, 355-367.
2. BRAŠIĆ, J. R. (2001) Quinine-induced thrombocytopenia in a 64-year-old man who consumed tonic water to relieve nocturnal leg cramps. Mayo Clinic Proceedings, 76, 863-864. [Letter]
3. BHINKER, A. D., & BEITZ, J. (2002) Spontaneous reports of thrombocytopenia in association with quinine: clinical attributes and timing related to regulatory action. American Journal of Hematology, 70, 313-317.
4. BURGESS, J. K. (2001) Molecular mechanisms of drug-induced thrombocytopenia. Current Opinion in Hematology, 8, 294-298.
5. Drug products containing active ingredients offered over-the-counter (OTC)for the treatment and/or prevention of nocturnal leg cramps. 21 C. F. R.§310.546. (2002) Washington, DC: U.S. Government Printing Office via GPO Access. P. 56.
6. Drug products containing quinine offered over-the-counter (OTC) for the treatment and/or prevention of malaria. 21 C. F. R.§310.547. (2002) Washington, DC: U.S. Government Printing Office via GPO Access. Pp. 56-57.
7. FALK, J. L., D'MELLO, K., & LAU, C. E. (2001) Two procedures establishing preference for oral cocaine and lidocaine solutions which do not use an associative history with a reinforcer. Behavioural Pharmacology, 12, 117-123.
8. FALK, J. L., YOSEF, E., SCHWARTZ, A., & LAU, C. E. (1999) Establishing oral preference for quinine, phencyclidine and caffeine solutions in rats. Behavioural Pharmacology, 10, 27-38.
9. HOWARD, M. A., HIBBARD, A. B., TERRELL, D. R., MEDINA, P. J., VESELY, S. K., & GEORGE, J. N. (2003) Quinine allergy causing acute severe systemic illness: report of 4 patients manifesting multiple hematologic, renal, and hepatic abnormalities. Baylor University Medical Center Proceedings, 16, 21-26.
10. KOJOURI, K., VESELY, S. K., & GEORGE, J. N. (2001) Quinine-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: frequency, clinical features, and longterm outcomes. Annals of Internal Medicine, 135, 1047-1051.
11. MEDINA, P. J., SIPOLS, T. M., & GEORGE, J. N. (2001) Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Current Opinion in Hematology, 8, 286-293.
12. MOAKE, J. L. (2002) Thrombotic microangiopathies. New England Journal of Medicine, 347, 589-600.
13. PETERSON, J. A., BOUGIE, D. W., GAULKE, T. J., VISENTIN, G. P., & ASTER, R. H. (2000) Antibodies from three patients with quinine-induced thrombocytopenia require a site between residues 50 and 67 on GPIIIa for binding the GPIIb/IIIa complex. Blood, 96(11)(Part 1 of 2 Parts), 814a-815a. [Abstract]
14. PISONI, R., RUGGENENTI, P., & REMUZZI, G. (2001) Drug-induced thrombotic microangiopathy: incidence, prevention and management. Drug Safety, 24, 491-501.
15. Quinine. 21 C. F .R. 172.575. (2002) Washington, DC: U.S. Government Printing Office via GPO Access. Pp. 61.